Teriparatide for osteoporosis - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Teriparatide for osteoporosis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001
Authors' objectives
To summarise the current research evidence on teriparatide (Forteo) for osteoporosis.
Authors' conclusions
- Clinical impact: Teriparatide is the first of a new class of drug for the management of osteoporosis-related fractures and because of the size of the patient group may lead to a significant clinical impact.
- Service impact: The introduction of teriparatide for osteoporosis is unlikely to cause a significant service impact. Although teriparatide increases the risk of transient hypercalcaemia routine monitoring is not thought to be necessary.
- Patient issues: Teriparatide is administered by subcutaneous injection and can be given by the patients themselves. This may limit its acceptability for some people.
- Financial and overall NHS impact: Because of its recombinant nature teriparatide may cost significantly more than current treatment options and this combined with the large potential patient group may lead to a significant overall effect.
Bone Density; Fractures, Bone; Osteoporosis /drug therapy; Teriparatide /therapeutic use
Language Published
English
Country of organisation
England
English summary
An English language summary is available.
Address for correspondence
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269 Email: c.packer@bham.ac.uk